Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Invitrogen Licenses Crucell's STAR technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Invitrogen Licenses Crucell’s STAR technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crucell N.V. has entered a non-exclusive STAR research license agreement with Invitrogen Corp.’s PD-Direct Bioprocess Services. The license covers the production of monoclonal antibodies.

According to Crucell, STAR technology is useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell’s PER.C6 human cell technology. The technology has the potential to reduce production costs by increasing production yields.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters